Low-dose radiation therapy: could it be a game-changer for COVID-19?
Angel Montero, Meritxell Arenas Prat, Manuel Ignacio Algara López
págs. 1-4
Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers
L.E. Pino, I. Triana, Carlos Eduardo Pérez Díaz, A. Piotrostanalzki, A. Ruiz Patiño, G. Lopes, Andrés Felipe Cardona Zorrilla
págs. 5-9
págs. 10-21
G. Baldelli, M. De Santi, M. Gervasi, G. Annibalini, Davide Sisti, Pernille Hojman, P. Sestili, Vilberto Stocchi, Elena Barbieri, G. Brandi
págs. 22-34
págs. 35-42
págs. 43-47
págs. 48-57
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group
Jorge Aparicio Urtasun, Xavier García del Muro Solans, Pablo Maroto Rey, Josefa Terrasa Pons, Daniel Castellano-Gauna, Romà Bastus Piulats, Josep Gumà Padró, N. Sagastibeltza, Ignacio Durán Martínez, S. Ochenduszko, José Andrés Meana, José García Sánchez, J. A. Arranz Arija, Regina Gironés Sarrió, Josep Ramon Germà Lluch
págs. 58-64
Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?
José Alberto Domínguez Alonso, David Conde Estévez, David Bosch Ros, Maria Pi-Figueras Valls, Ignacio Tusquets Trias de Bes
págs. 65-73
págs. 74-81
Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
págs. 82-91
Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia
págs. 92-99
Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis
págs. 100-109
págs. 110-121
Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study
Pilar García Alfonso, G. García González, I. Gallego, María Isabel Peligros Gómez, L. Ortega Morán, G. Torres Pérez-Solero, C. Sandoval García, Andrés Jesús Muñoz Martín, Montserrat Blanco Codesido, Aitana Calvo Ferrándiz, Miguel Martín Jiménez
págs. 122-129
págs. 130-138
Prognostic value of neutrophil–lymphocyte ratio in critically ill patients with cancer: a propensity score matching study
Z.-Q. Chen, X.-S. Yu, L.-J. Mao, R. Zheng, L.-L. Xue, J. Shu, Z.-W. Luo, J.-Y. Pan
págs. 139-147
págs. 148-154
págs. 155-163
Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study
págs. 164-171
PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer
Egesta Lopci, G. Lughezzani, A. Castello, P. Colombo, P. Casale, A. Saita, N.M. Buffi, G. Guazzoni, Arturo Chiti, M. Lazzeri
págs. 172-178
Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis
J. Burgos Burgos, Víctor Vega Benítez, David Macias Verde, V. Gómez, María del Mar Travieso Aja, J. Travieso, E. Vicente Rubio, C. Santana, J. Ospina, Pedro Lara Jiménez
págs. 179-182
Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Alba Rubio San Simón, J. Verdu Amoros, R. Hladun, A. Juan Ribelles, Marta Molero Luis, Pilar Guerra García, Antonio Pérez Martínez, Alicia Castañeda Heredia, María Adela Cañete Nieto, Teresa de Rojas de Pablo, Lucas Moreno, F. J. Bautista Sirvent
págs. 183-189
págs. 190-194
© 2001-2025 Fundación Dialnet · Todos los derechos reservados